A study to determine safety of Durvalumab after sequential chemo radiation in patients with unresectable Stage III Non-Small Cell Lung Cancer

Trial Identifier: D4194C00006
Sponsor: AstraZeneca
NCTID:: NCT03693300
Start Date: April 2019
Primary Completion Date: December 2022
Study Completion Date: April 2023
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
German Translation
Spanish Translation
French Translation
Italian Translation

Trial Locations

Country Location
DE Gauting, DE, 82131
DE Grosshansdorf, DE, 22927
DE Grosshansdorf, DE, 22927
DE Hamm, DE, 59063
DE Hannover, DE, 30459
DE Heidelberg, DE, 69126
ES Barcelona, ES, 08907
ES Guadalajara, ES, 19002
ES Madrid, ES, 28041
ES Sevilla, ES, 41013
ES Valencia, ES, 46015
FR Creteil, FR, 94010
FR Paris Cedex 05, FR, 75248
FR Saint Priest en Jarez, FR, 42270
FR Toulouse Cedex 9, FR, 31400
GB Leeds, GB, LS9 7TF
GB Manchester, GB, M20 4BX
GB Nottingham, GB, NG5 1PB
GB Sheffield, GB, S10 2SJ
GB Stoke on Trent, GB, ST4 6QG
IT Avellino, IT, 83100
IT Meldola, IT, 47014
IT Milano, IT, 20133
IT Monza, IT, 20900
IT Parma, IT, 43126
IT Roma, IT, 00152
US, GA Gainesville, GA, US, 30501
US, TN Knoxville, TN, US, 37920